{"entity":{"id":"nct05909436","kind":"trial","name":"Immuno-Oncology Drugs GLS-012 Alone & in Combination GLS-010 Treating With Advanced Patients Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of Zimberelimab in advanced solid tumours, run by Guangzhou Gloria Biosciences Co., Ltd., now recruiting.","summary":"Immuno-Oncology Drugs GLS-012 Alone & in Combination GLS-010 Treating With Advanced Patients Solid Tumors is a phase 1/2 interventional study registered as NCT05909436 by Guangzhou Gloria Biosciences Co., Ltd., with 107 participants planned, started 2022-10-31 and due to reach its primary completion in 2026-12. Interventions recorded: GLS-012 and GLS-010.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05909436","url":"https://clinicaltrials.gov/study/NCT05909436"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["zimberelimab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05909436","phase":"1/2","setting":"A Phase I/II Study Evaluating the Safety, Tolerability and Preliminary Efficacy of GLS-012 Monotherapy and in Combination With GLS-010 in Patients With Advanced Solid Tumors After Progression on Standard Treatment (Triumph-01)","sponsor":"Guangzhou Gloria Biosciences Co., Ltd.","enrolled":107,"outcomes":[]},"route":"/trials/nct05909436/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"zimberelimab","kind":"drug","name":"Zimberelimab","route":"/drugs/zimberelimab/"}]}}